Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 2Thoracic 1

Conditions

Small Cell Lung Carcinoma 9Lung Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Fallopian Tube Neoplasms 1Extensive Stage Small Cell Lung Cancer 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Small Cell 1Carcinoma, Pancreatic Ductal 1Carcinoma, Neuroendocrine 1

Interventions

atezolizumab 4Nivolumab 4Cisplatin 4Topotecan 2Radiosurgery 2Paclitaxel 2Ipilimumab 2Immunoglobulin G 2Etoposide 2Disulfides 2veliparib 1tocilizumab 1repotrectinib 1pralsetinib 1pembrolizumab 1niraparib 1iadademstat 1durvalumab 1dostarlimab 1cabozantinib 1budigalimab 1berzosertib 1belinostat 1Temozolomide 1Specimen Handling 1Radiotherapy 1Podophyllotoxin 1Platinum 1Magnetic Resonance Spectroscopy 1Irinotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Neuroendocrine × EC regimen × Thoracic × Clear all
NCT05652686 2025-09-23

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

Phanes Therapeutics

Phase 1/2 Recruiting
203 enrolled
EndocrineThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡